Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Rating of “Hold” by Analysts

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have been given a consensus recommendation of “Hold” by the ten analysts that are currently covering the stock, MarketBeat.com reports. Eight analysts have rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company.

A number of equities research analysts have commented on ZLDPF shares. Jefferies Financial Group cut shares of Zealand Pharma A/S to a “hold” rating in a research note on Monday. Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Wolfe Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th.

Zealand Pharma A/S Stock Performance

OTCMKTS:ZLDPF opened at $44.86 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17. The stock has a 50-day simple moving average of $46.88 and a two-hundred day simple moving average of $52.79. The firm has a market capitalization of $3.21 billion, a PE ratio of 3.33 and a beta of 0.88. Zealand Pharma A/S has a 52-week low of $35.93 and a 52-week high of $83.12.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%.The firm had revenue of $5.33 million for the quarter, compared to the consensus estimate of $2.81 million. Analysts forecast that Zealand Pharma A/S will post 2.37 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.